
Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target
Aurinia Pharmaceuticals (AUPH) Analyst Ratings
Bulls say
Aurinia Pharmaceuticals is projected to generate significant revenue growth, with risk-adjusted product revenues expected to reach $243.7 million in 2025 and soar to $932.3 million by 2033. Additionally, the projected revenue from aritinercept reflects potential growth from $15.4 million in 2030 to $281.6 million by 2033, contingent on successful market entry. Furthermore, the anticipated positive impact of the 2024 ACR LN guideline is expected to enhance the growth trajectory of LUPKYNIS starting in 2027, indicating robust future demand for the company's therapies.
Bears say
Aurinia Pharmaceuticals has demonstrated challenges in maintaining consistent sales growth, which raises concerns regarding its financial sustainability amidst a competitive biopharmaceutical landscape. The reported increase in adverse effects related to its marketed product, LUPKYNIS, may adversely impact patient adherence and market perception, further complicating future revenue generation. Additionally, ongoing developmental costs associated with its pipeline product, AUR200, could strain financial resources, potentially limiting the company’s ability to achieve profitability in the near term.
This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction
Start investing in Aurinia Pharmaceuticals (AUPH)
Order type
Buy in
Order amount
Est. shares
0 shares